Abstract
Antibody–drug conjugates (ADCs) are highly potent targeted anticancer therapies. They rely on the linking of a selectively targeting antibody moiety with potent cytotoxic payloads to effect antitumoral activity. In recent years, one focus in the ADC field was to create novel methods for site-specifically conjugating payloads to antibodies. The method presented here is based on the S. aureus sortase A-mediated transpeptidation reaction. This method requires antibodies to be engineered in such a way that they possess the sortase recognition pentapeptide motif LPETG on the C-terminus of the immunoglobulin heavy and/or light chains. In addition, the toxin must contain an oligoglycine motif in order to make it a suitable substrate for sortase A. Here we describe a detailed method to conjugate a pentaglycine-modified toxin to the C-termini of LPETG-tagged antibody heavy and light chains using sortase-mediated antibody conjugation (SMAC-Technology™). Highly homogenous, site-specifically conjugated ADCs with controlled drug to antibody ratio and improved overall properties can be obtained with this method.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsSpringer Nature is developing a new tool to find and evaluate Protocols. Learn more
References
Beck A, Goetsch L, Dumontet C et al (2017) Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov 19:869
Carter PJ, Lazar GA (2018) Next generation antibody drugs: pursuit of the ‘high-hanging fruit’. Nat Rev Drug Discov 17:197–223
Lambert JM, Berkenblit A (2018) Antibody-drug conjugates for cancer treatment. Annu Rev Med 69:191–207
Gébleux R, Casi G (2016) Antibody-drug conjugates: current status and future perspectives. Pharmacol Ther 167:48–59
Schumacher D, Hackenberger CPR, Leonhardt H et al (2016) Current status: site-specific antibody drug conjugates. J Clin Immunol 36(Suppl 1):100–107
Beerli RR, Grawunder U (2017) Enzyme-based strategies to generate site-specifically conjugated antibody drug conjugates. In: Next generation antibody drug conjugates (ADCs) and immunotoxins. Springer International Publishing, Cham, pp 85–106
Mao H, Hart SA, Schink A et al (2004) Sortase-mediated protein ligation: a new method for protein engineering. J Am Chem Soc 126:2670–2671
Tsukiji S, Nagamune T (2009) Sortase-mediated ligation: a gift from Gram-positive bacteria to protein engineering. Chembiochem 10:787–798
Popp MW, Antos JM, Grotenbreg GM et al (2007) Sortagging: a versatile method for protein labeling. Nat Chem Biol 3:707–708
Parthasarathy R, Subramanian S, Boder ET (2007) Sortase A as a novel molecular “stapler” for sequence-specific protein conjugation. Bioconjug Chem 18:469–476
Theile CS, Witte MD, Blom AEM et al (2013) Site-specific N-terminal labeling of proteins using sortase-mediated reactions. Nat Protoc 8:1800–1807
Möhlmann S, Mahlert C, Greven S et al (2011) In vitro sortagging of an antibody fab fragment: overcoming unproductive reactions of sortase with water and lysine side chains. Chembiochem 12:1774–1780
Madej MP, Coia G, Williams CC et al (2012) Engineering of an anti-epidermal growth factor receptor antibody to single chain format and labeling by Sortase A-mediated protein ligation. Biotechnol Bioeng 109:1461–1470
Massa S, Vikani N, Betti C et al (2016) Sortase A-mediated site-specific labeling of camelid single-domain antibody-fragments: a versatile strategy for multiple molecular imaging modalities. Contrast Media Mol Imaging 11:328–339
Beerli RR, Hell T, Merkel AS et al (2015) Sortase enzyme-mediated generation of site-specifically conjugated antibody drug conjugates with high in vitro and in vivo potency. PLoS One 10:e0131177
Stefan N, Gébleux R, Waldmeier L et al (2017) Highly potent, anthracycline-based antibody-drug conjugates generated by enzymatic, site-specific conjugation. Mol Cancer Ther 16:879–892
Mazmanian SK, Liu G, Ton-That H et al (1999) Staphylococcus aureus sortase, an enzyme that anchors surface proteins to the cell wall. Science 285:760–763
Ton-That H, Liu G, Mazmanian SK et al (1999) Purification and characterization of sortase, the transpeptidase that cleaves surface proteins of Staphylococcus aureus at the LPXTG motif. Proc Natl Acad Sci U S A 96:12424–12429
Chen I, Dorr BM, Liu DR (2011) A general strategy for the evolution of bond-forming enzymes using yeast display. Proc Natl Acad Sci U S A 108:11399–11404
Chen Y (2013) Drug-to-antibody ratio (DAR) by UV/Vis spectroscopy. Methods Mol Biol (Clifton, N.J.) 1045:267–273
Ouyang J (2013) Drug-to-antibody ratio (DAR) and drug load distribution by hydrophobic interaction chromatography and reversed phase high-performance liquid chromatography. Methods Mol Biol (Clifton, N.J.) 1045:275–283
Su D, Ng C, Khosraviani M et al (2016) Custom-designed affinity capture LC-MS F(ab′)2 assay for biotransformation assessment of site-specific antibody drug conjugates. Anal Chem 88:11340–11346
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Gébleux, R., Briendl, M., Grawunder, U., Beerli, R.R. (2019). Sortase A Enzyme-Mediated Generation of Site-Specifically Conjugated Antibody–Drug Conjugates. In: Nuijens, T., Schmidt, M. (eds) Enzyme-Mediated Ligation Methods. Methods in Molecular Biology, vol 2012. Humana, New York, NY. https://doi.org/10.1007/978-1-4939-9546-2_1
Download citation
DOI: https://doi.org/10.1007/978-1-4939-9546-2_1
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-4939-9545-5
Online ISBN: 978-1-4939-9546-2
eBook Packages: Springer Protocols